These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36289797)

  • 1. Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.
    Stork M; Sevcikova S; Jelinek T; Minarik J; Radocha J; Pika T; Pospisilova L; Spicka I; Straub J; Pavlicek P; Jungova A; Knechtova Z; Sandecka V; Maisnar V; Hajek R; Pour L
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of patients at high risk of secondary extramedullary multiple myeloma development.
    Stork M; Sevcikova S; Minarik J; Krhovska P; Radocha J; Pospisilova L; Brozova L; Jarkovsky J; Spicka I; Straub J; Pavlicek P; Jungova A; Jelinek T; Sandecka V; Maisnar V; Hajek R; Pour L
    Br J Haematol; 2022 Feb; 196(4):954-962. PubMed ID: 34726261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].
    Zhao JT; Jiang XY; Yang C; Chen M; Lan XL; Du JH; Zhou DB; Zhuang JL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):295-301. PubMed ID: 33979973
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic value of semi-quantitative parameters of
    Wan B; Zhang S; Wang P; Deng P; Dai W
    Ann Nucl Med; 2023 Mar; 37(3):155-165. PubMed ID: 36528697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow fibrosis in newly diagnosed multiple myeloma and its correlation with clinicopathological factors.
    Hu X; Dai X; Guo X; Jiang X; Li Y; Zhao H; Lu J; Li X; Jin M
    Diagn Pathol; 2024 Jul; 19(1):99. PubMed ID: 39026319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
    Rosiñol L; Beksac M; Zamagni E; Van de Donk NWCJ; Anderson KC; Badros A; Caers J; Cavo M; Dimopoulos MA; Dispenzieri A; Einsele H; Engelhardt M; Fernández de Larrea C; Gahrton G; Gay F; Hájek R; Hungria V; Jurczyszyn A; Kröger N; Kyle RA; Leal da Costa F; Leleu X; Lentzsch S; Mateos MV; Merlini G; Mohty M; Moreau P; Rasche L; Reece D; Sezer O; Sonneveld P; Usmani SZ; Vanderkerken K; Vesole DH; Waage A; Zweegman S; Richardson PG; Bladé J
    Br J Haematol; 2021 Aug; 194(3):496-507. PubMed ID: 33724461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC translocation is a valuable marker for the development and relapse of extramedullary disease in multiple myeloma.
    Song Y; Du J; Jin X; Li H; Jia C; Liu Y; Li K; Zhou D; Zhuang J
    Eur J Haematol; 2024 Dec; 113(6):824-832. PubMed ID: 39191670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study.
    Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H
    Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients.
    Vuckovic S; Bryant CE; Lau KHA; Yang S; Favaloro J; McGuire HM; Clark G; de St Groth BF; Marsh-Wakefield F; Nassif N; Abadir E; Vanguru V; McCulloch D; Brown C; Larsen S; Dunkley S; Khoo L; Gibson J; Boyle R; Joshua D; Ho PJ
    Blood Adv; 2020 Oct; 4(19):4593-4604. PubMed ID: 32986791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma.
    Batsukh K; Lee SE; Min GJ; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Min CK
    Immune Netw; 2017 Aug; 17(4):250-260. PubMed ID: 28860954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extramedullary disease in multiple myeloma: a systematic literature review.
    Bladé J; Beksac M; Caers J; Jurczyszyn A; von Lilienfeld-Toal M; Moreau P; Rasche L; Rosiñol L; Usmani SZ; Zamagni E; Richardson P
    Blood Cancer J; 2022 Mar; 12(3):45. PubMed ID: 35314675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral Orbital Plasmacytomas With Orbital Compartment Syndrome.
    Pyon RE; Wang GC; Chu Y; Tulpule S
    Cureus; 2022 Jun; 14(6):e26269. PubMed ID: 35898379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse skeletal muscle extramedullary plasmacytomas: a rare case and review of the literature.
    Moore RD; Nelson SM; Cecava ND
    Skeletal Radiol; 2020 Dec; 49(12):2087-2093. PubMed ID: 32556470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive extramedullary disease in myeloma. An uncommon variant with features of poor prognosis and dedifferentiation.
    Sanal SM; Yaylaci M; Mangold KA; Pantazis CG
    Cancer; 1996 Apr; 77(7):1298-302. PubMed ID: 8608506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma.
    Terao T; Machida Y; Narita K; Kuzume A; Tabata R; Tsushima T; Miura D; Takeuchi M; Tateishi U; Matsue K
    Eur Radiol; 2021 Aug; 31(8):6136-6144. PubMed ID: 33496828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
    Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
    Peng KW; Dogan A; Vrana J; Liu C; Ong HT; Kumar S; Dispenzieri A; Dietz AB; Russell SJ
    Am J Hematol; 2009 Jul; 84(7):401-7. PubMed ID: 19507209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
    Jiménez-Segura R; Granell M; Gironella M; Abella E; García-Guiñón A; Oriol A; Cabezudo E; Clapés V; Soler JA; Escoda L; López-Pardo J; Fernández de Larrea C; Cibeira MT; Tovar N; Isola I; Bladé J; Rosiñol L;
    Eur J Haematol; 2019 May; 102(5):389-394. PubMed ID: 30719772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor.
    Wang Y; Liu A; Xu T; Yin J; Chen W
    Clin Med Insights Oncol; 2022; 16():11795549221109500. PubMed ID: 35875418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.